Publication | Closed Access

Luteolin as a glycolysis inhibitor offers superior efficacy and lesser toxicity of doxorubicin in breast cancer cells

Breast OncologyOncologyMedicineBreast Cancer CellsPathologyGlycolysis InhibitorLesser ToxicityBreast CancerPharmacotherapyAnti-cancer AgentCancer TreatmentPharmacologyTumor Microenvironment